standard of care in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 (REV) 1.44 [0.59; 3.51]
1.44 [0.59 ; 3.51 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable deathsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 (REV) 1.52 [0.03; 82.26]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 0.68 [0.22; 2.09]
FACCT Trial, 2021 (REV) 1.04 [0.48; 2.26]
HC-nCoV (Shanghai), 2020 (REV) 1.00 [0.02; 53.89]
0.92 [0.50 ; 1.72 ] ChiCTR2000030054-HCQ (Chen), 2020 (REV), Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV), FACCT Trial, 2021 (REV), HC-nCoV (Shanghai), 2020 (REV) 4 0% 646 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 0.83 [0.47; 1.45]
Kamran, 2020 (REV) 1.05 [0.36; 3.08]
Zhaowei Chen, 2020 (REV) 9.04 [0.46; 178.86]
0.98 [0.52 ; 1.86 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV), Kamran, 2020 (REV), Zhaowei Chen, 2020 (REV) 3 18% 894 moderate not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1.21 [0.69; 2.12]
1.21 [0.69 ; 2.12 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1 0% 448 NA not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 (REV) 1.18 [0.86; 1.62]
1.18 [0.86 ; 1.62 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable hospital dischargedetailed results FACCT Trial, 2021 (REV) 1.14 [0.83; 1.57]
1.14 [0.83 ; 1.57 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable radiologic improvement (7-day)detailed results Zhaowei Chen, 2020 (REV) 0.29 [0.09; 0.91]
0.29 [0.09 ; 0.91 ] Zhaowei Chen, 2020 (REV) 1 0% 62 NA not evaluable viral clearance detailed results HC-nCoV (Shanghai), 2020 (REV) 2.15 [0.17; 26.67]
2.15 [0.17 ; 26.67 ] HC-nCoV (Shanghai), 2020 (REV) 1 0% 30 NA not evaluable ICU admissiondetailed results FACCT Trial, 2021 (REV) 0.70 [0.39; 1.26]
0.70 [0.39 ; 1.26 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable adverse eventsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 (REV) 0.20 [0.03; 1.18]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1.14 [0.38; 3.42]
HC-nCoV (Shanghai), 2020 (REV) 0.69 [0.12; 3.79]
0.65 [0.24 ; 1.73 ] ChiCTR2000030054-HCQ (Chen), 2020 (REV), Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV), HC-nCoV (Shanghai), 2020 (REV) 3 25% 392 serious not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-06 08:05 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
